Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The leading cause of maternal deaths in the UK is still cardiovascular disease, including heart attacks, heart failure and heart rhythm problems, and there has been no reduction in maternal cardiovascular mortality rates for more than 15 years.

These are the main findings of a new report, Saving Lives, Improving Mothers’ Care, from the National Perinatal Epidemiology Unit (NPEU), part of the Nuffield Department of Population Health (NDPH) at the University of Oxford.

The report is the latest produced for the Maternal, Newborn and Infant Clinical Outcome Review Programme, run by the MBRRACE-UK (Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across the UK) collaboration. The authors analysed 2.3m pregnancies from 2015-2017 in the UK and Ireland. During that three-year period, 209 women in the UK and Ireland died during their pregnancies or up to six weeks afterwards from pregnancy-related causes. This is equivalent to just over nine women per 100,000.

Of the women who died, 48, or 23%, died from heart disease, while 16% died from blood clots. A further 13% of women’s deaths were caused by epilepsy and stroke.

When the deaths were reviewed, the researchers found that many of the women who died from cardiovascular disease had classic symptoms that would have been flagged in a non-pregnant person, but instead were put down to their pregnancy. Three quarters of the women who died did not know they had heart disease before they became pregnant.

Read more (University of Oxford)

Similar stories

Oxford University wins prestigious Queen’s Anniversary Prize

Her Majesty The Queen has approved the award of The Queen’s Anniversary Prizes to twenty-one higher and further education institutions, including Oxford University, in the most recent round of the independently reviewed scheme. This prestigious award is the highest national honour available to universities and FE colleges across the UK.

Jenner Institute named Covid Innovation Heroes

The team at the University of Oxford’s Jenner Institute has been celebrated for their global pandemic work by The Oxford Trust’s Covid Innovation Heroes Award­ 2021.

Study reveals ‘stop-eating’ response to DNA damage

A new study from the MRC Weatherall Institute of Molecular Medicine sheds light on the mechanism by which DNA damage suppresses appetite, a finding with implications for understanding the appetite lowering side-effects of chemotherapy.

Fiona Powrie appointed new Deputy Chair of Wellcome’s Board of Governors

Fiona Powrie, Director of the Kennedy Institute of Rheumatology at the University of Oxford has been selected as the next Deputy Chair of Wellcome’s Board of Governors.

World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition

Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.